MIROCALS consortium is formed by 12 organisations in the EU to conduct a phase II Proof of Concept / Proof of Mechanism Clinical Trial aiming to test the interleukin-2 (IL-2) as treatment for amyotrophic lateral sclerosis (ALS).

The science of the project is coordinated by Dr Gilbert Bensimon of the University Hospital of Nimes (France) which is the trial sponsor, and Professor P. Nigel Leigh of the Brighton and Sussex Medical School (UK).

Around them, the MIROCALS consortium brings together a strong partnership of: leading scientists and clinicians from six European laboratories in France, Italy, Sweden and UK; two clinical research organisations for professional biobanking and trial regulatory-compliant monitoring; the MND Association one of the most active patients’ associations in the field of neurodegeneration worldwide and an EU project management company.

MIROCALS is a 4-year collaborative research project started in September 2015 and supported by the European Union’s Horizon 2020 research and innovation Programme.

 

University Hospital of Nimes Nîmes, France	Inserm Transfert Paris, France
ICON plc Ireland	Genethon Evry, France
Humanitas Research Hospital Milan, Italy	University of Gothenburg Sweden
University of Sussex UK	University of Sheffield UK
King's College London London, UK	Queen Mary University London, UK
Motor Neurone Disease Association UK	WGK Consultancy Ltd UK